Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Persevera is a bust, but Roche hasn’t given up on the front line.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The company pays $2.5bn for Day One and its approved drug Ojemda.
Ono's antisense therapy is to begin its first pivotal trial.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
